Elicio Therapeutics (ELTX) Preferred Stock Liabilities (2021 - 2023)
Elicio Therapeutics' (ELTX) quarterly Preferred Stock Liabilities came in at $111.1 million in Q1 2023, up 57.67% YoY from $70.4 million in Q1 2022, and little changed on a QoQ basis from $111.1 million in Q4 2022.
Elicio Therapeutics (ELTX) Preferred Stock Liabilities (2021 - 2023) Analysis & Trends
Elicio Therapeutics (ELTX) has 3 years of Preferred Stock Liabilities data on file, last reported at $111.1 million in Q1 2023.
- Quarterly Preferred Stock Liabilities rose 57.67% year-over-year to $111.1 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $111.1 million (up 57.67% YoY) and the FY2022 annual result came in at $111.1 million, up 57.67% from the prior year.
- Preferred Stock Liabilities steadied at $111.1 million in Q1 2023, from $111.1 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $111.1 million in Q4 2022 to a low of $70.4 million in Q4 2021.
- A 3-year average of $85.8 million and a median of $76.0 million in 2022 frame the typical range for Preferred Stock Liabilities.
- The widest YoY moves for Preferred Stock Liabilities: up 57.67% in 2022, down 57.67% in 2022.
- Tracing ELTX's Preferred Stock Liabilities over 3 years: stood at $70.4 million in 2021, then soared by 57.67% to $111.1 million in 2022, then changed by 0.0% to $111.1 million in 2023.
- The last three Preferred Stock Liabilities figures came in at $111.1 million (Q1 2023), $111.1 million (Q4 2022), and $80.4 million (Q3 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 111.06 Mn |
| Dec 31, 2022 | 111.06 Mn |
| Sep 30, 2022 | 80.45 Mn |
| Jun 30, 2022 | 71.61 Mn |
| Mar 31, 2022 | 70.44 Mn |
| Dec 31, 2021 | 70.44 Mn |